The role of fatty acid hydrolase gene variants in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 5, 2009, Pages 542-551

  Storr, M ^a,b,c   Emmerdinger, D ^a   Diegelmann, J ^a   Yuce B ^a   Pfennig, S ^a   Ochsenkuhn T ^a   Goke B ^a   Lohse, P ^a   Brand, S ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID AMIDASE; GENOMIC DNA; INTERLEUKIN 8; MESSENGER RNA;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; ENTERITIS; FAAH GENE; FEMALE; FISTULA; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AMIDOHYDROLASES; CHILD; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTOR, CANNABINOID, CB1; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 59149106903     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03910.x     Document Type: Article

References (52)

1. Grinspoon L, Bakalar JB. Marihuana as medicine. A plea for reconsideration. JAMA 1995 273 : 1875 6.
2. Grinspoon L. The future of medical marijuana. Forsch Komplementärmed 1999 6 (Suppl 3 40 3.
3. Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002 122 : 2032 48.
4. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002 51 (Suppl 1 i41 4.
5. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002 54 : 161 202.
6. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002 66 : 123 42.
7. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003 4 : 873 84.
8. Cravatt BF, Lichtman AH. The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 2002 121 : 135 48.
9. Storr M, Sibaev A, Marsicano G, et al. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol 2004 286 : G110 7.
10. Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000 302 : 73 80.
11. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002 448 : 410 22.
12. Pinto L, Izzo AA, Cascio MG, et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002 123 : 227 34.
13. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001 48 : 859 67.
14. Jaggar SI, Sellaturay S, Rice AS. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci Lett 1998 253 : 123 6.
15. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005 129 : 437 53.
16. Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003 125 : 677 87.
17. Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 2003 12 : 39 49.
18. Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001 1 : 597 603.
19. Pinto L, Capasso R, Di Carlo G, Izzo AA. Endocannabinoids and the gut. Prostaglandins Leukot Essent Fatty Acids 2002 66 : 333 41.
20. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004 141 : 765 74.
21. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004 113 : 1202 9.
22. Izzo AA, Camilleri M. Emerging role of Cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008 57 : 1140 55.
23. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006 291 : G364 71.
24. D'Argenio G, Valenti M, Scaglione G, et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006 20 : 568 70.
25. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A 2002 99 : 8394 9.
26. Cravatt BF, Saghatelian A, Hawkins EG, et al. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A 2004 101 : 10821 6.
27. 2 receptors. J Mol Med 2008 86 : 925 36.
28. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000 6 : 8 15.
29. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005 19 (Suppl A 5 36.
30. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 2004 13 : 2113 9.
31. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001 89 : 401 7.
32. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006 290 : G827 38.
33. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 411 : 603 6.
34. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 411 : 599 603.
35. Weersma RK, Zhernakova A, Nolte IM, et al. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in The Netherlands. Am J Gastroenterol 2007 103 : 621 7.
36. Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. Autophagy 2007 3 : 649 51.
37. Franke A, Hampe J, Rosenstiel P, et al. Systematic association mapping identifies NELL1 as a novel IBD disease gene. PLoS ONE 2007 2 : e691.
38. Roberts RL, Gearry RB, Hollis-Moffatt JE, et al. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am J Gastroenterol 2007 102 : 2754 61.
39. Glas J, Konrad A, Schmechel S, et al. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population. Am J Gastroenterol 2007 103 : 682 91.
40. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996 58 : 694 702.
41. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002 359 : 1661 5.
42. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2 Implications for Crohn's disease. J Biol Chem 2003 278 : 5509 12.
43. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001 357 : 1925 8.
44. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008 40 : 955 62.
45. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995 310 : 170.
46. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998 316 : 1236 8.
47. Massa F, Sibaev A, Marsicano G, et al. Vanilloid receptor (TRPV-1) deficient mice show increased susceptibility to dinitrobenzene sulfonic acid-induced colitis. J Mol Med 2006 84 : 142 6.
48. Sibaev A, Massa F, Yuce B, et al. CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. J Mol Med 2006 84 : 513 20.
49. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993 46 : 791 6.
50. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001 98 : 9371 6.
51. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 2005 29 : 755 9.
52. Morita Y, Ujike H, Tanaka Y, et al. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci Lett 2005 376 : 182 7.